0001193125-15-344710.txt : 20151118 0001193125-15-344710.hdr.sgml : 20151118 20151015160559 ACCESSION NUMBER: 0001193125-15-344710 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20151015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vascular Biogenics Ltd. CENTRAL INDEX KEY: 0001603207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 BUSINESS PHONE: 972-3-6346450 MAIL ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 CORRESP 1 filename1.htm Acceleration Request

Vascular Biogenics Ltd.

6 Jonathan Netanyahu St.

Or Yehuda

Israel 60376

VIA EDGAR AND FEDERAL EXPRESS

October 15, 2015

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-4720

 

Re: Vascular Biogenics Ltd.

Acceleration Request for Registration Statement on Form F-3

File No. 333-207250

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Vascular Biogenics Ltd. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to October 19, 2015, at 4:00 p.m., Eastern Time, or as soon thereafter as possible.

In connection with the foregoing, the Company hereby acknowledges the following:

 

  •   should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

  •   the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

  •   the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you have any questions regarding this request, please contact Lawrence S. Wittenberg of Goodwin Procter LLP at (617) 570-1035.

Sincerely,

VASCULAR BIOGENICS LTD.

/s/ Dror Harats

Dror Harats

Chief Executive Officer

 

cc: Amos Ron, Vascular Biogenics Ltd.

Lawrence S. Wittenberg, Goodwin Procter LLP

James Xu, Goodwin Procter LLP